M2698
Cat. No.：YN350006
CAS No. ：1379545-95-5
| 产品名称: | M2698 |
| CAS No.: | 1379545-95-5 |
| Chemical Name: | 4-[[(1S)-2-(1-azetidinyl)-1-[4-chloro-3-(trifluoromethyl)phenyl]ethyl]amino]-8-quinazolinecarboxamide |
| Synonyms: | MSC2363318A |
| 分子量: | 449.86 |
| 分子式: | C₂₁H₁₉ClF₃N₅O |
| SMILES: | O=C(C1=CC=CC2=C(N[C@@H](C3=CC=C(Cl)C(C(F)(F)F)=C3)CN4CCC4)N=CN=C12)N |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | M2698 (MSC2363318A) 是一种具有口服活性，ATP 竞争的，选择性的p70S6K和Akt双重抑制剂，对于 p70S6K，Akt1 和 Akt3 的IC50均为 1 nM。M2698 可以透过血脑屏障，具有抗癌活性。 |
| IC50和靶点: | [{name:"p70S6K:1 nM (IC50)"},{name: "Akt1:1 nM (IC50)"},{name: "Akt3:1 nM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
DeSelm, L., Huck, B., Lan, R., et al.Identification of clinical candidate M2698, a dual p70S6K and Akt inhibitor, for treatment of PAM pathway-altered cancersJ. Med. Chem.64(19),14603-14619(2021)
